Grants and Contributions:
Title:
Development of the Amplifier antibody platform, its proof of concept and a therapeutic candidate.
Agreement Number:
1013408
Agreement Value:
$530,500.00
Agreement Date:
Oct 15, 2023 - Nov 30, 2024
Description:
This project will develop and characterize the function of Amplifier antibodies, a novel class of multispecific antibodies that engage cytokines and redirect them to a desired tissue or target cell for enhanced exposure and targeted activity.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Vancouver, British Columbia, CA V7Y 1B3
Reference Number:
172-2023-2024-Q3-1013408
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
748263746
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 61 days.
Amendment Date
Sep 24, 2024
Recipient's Legal Name:
Reverb Therapeutics Inc.
Federal Riding Name:
Vancouver Centre
Federal Riding Number:
59034
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: